49 related articles for article (PubMed ID: 28725988)
21. Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.
Chiavazza C; Pellerino A; Ferrio F; Cistaro A; Soffietti R; Rudà R
Biomed Res Int; 2018; 2018():3606970. PubMed ID: 30035121
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.
Birsen R; Blanc E; Willems L; Burroni B; Legoff M; Le Ray E; Pilorge S; Salah S; Quentin A; Deau B; Franchi P; Vignon M; Mabille L; Nguyen C; Kirova Y; Varlet P; Edjlali M; Dezamis E; Hoang-Xuan K; Soussain C; Houillier C; Damotte D; Pallud J; Bouscary D; Tamburini J
Oncotarget; 2018 Mar; 9(24):16822-16831. PubMed ID: 29682187
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
[TBL] [Abstract][Full Text] [Related]
24. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
27. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
28. Interim
Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
[No Abstract] [Full Text] [Related]
29. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560
[TBL] [Abstract][Full Text] [Related]
31. Effect of rituximab on primary central nervous system lymphoma: a meta-analysis.
Song Y; Wen Y; Xue W; Zhang Y; Zhang M
Int J Hematol; 2017 Nov; 106(5):612-621. PubMed ID: 28900847
[TBL] [Abstract][Full Text] [Related]
32. Primary Suprasellar Hypothalamic CNS Lymphoma in an Immunocompetent Adult: A Case Report and Review of Literature.
Mohanty CB; Muley KD; Deopujari CE
Neurol India; 2020; 68(6):1435-1438. PubMed ID: 33342884
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]